Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal, preferably in the evening, and increase the dose gradually.
To preserve the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it.
Take one 100/1000 mg extended-release tablet once daily.
Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine.
2. Patients receiving metformin:
The recommended initial total daily dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the current metformin dose.
Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin.
Patients previously taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start this medicine at 2 tablets of 50/1000 mg extended-release tablets once daily.
3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial total daily dose of this medicine is sitagliptin 100 mg. The initial dose of metformin should be determined taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Patients with hepatic impairment
This medicine should not be administered to patients with hepatic impairment because of its metformin component.
Improvement of glycemic control in type 2 diabetes mellitus
View approved original textHide original text
This medication helps patients with type 2 diabetes more effectively manage their blood sugar levels while adhering to diet and exercise regimens. Sitagliptin and metformin work together to help maintain stable blood sugar levels. Therefore, it is used to improve blood sugar control in diabetic patients.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal, preferably in the evening, and increase the dose gradually.
To preserve the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it.
Take one 100/1000 mg extended-release tablet once daily.
Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin.
Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine.
2. Patients receiving metformin:
The recommended initial total daily dose of this medicine for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the current metformin dose.
Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin.
Patients previously taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start this medicine at 2 tablets of 50/1000 mg extended-release tablets once daily.
3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial total daily dose of this medicine is sitagliptin 100 mg. The initial dose of metformin should be determined taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin.
Patients with renal impairment
This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment.
Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
Patients with hepatic impairment
This medicine should not be administered to patients with hepatic impairment because of its metformin component.
Precautions
This medication consists of two components, sitagliptin and metformin, and is mainly used for the treatment of type 2 diabetes.
First, sitagliptin may rarely cause serious allergic reactions, so if symptoms such as rash, hives, or difficulty breathing occur, discontinue taking the medication immediately and consult a physician.
There is also a risk of acute pancreatitis, which is inflammation of the pancreas, so it is important to carefully monitor for symptoms such as abdominal pain, vomiting, and severe abdominal discomfort, and discontinue use if symptoms occur.
Metformin can cause lactic acidosis, a rare but very serious metabolic complication, so patients with impaired kidney function or liver disease should not take this medication. Additionally, it should be avoided in conditions that can affect kidney function such as dehydration, severe infections, heart failure, and acute myocardial infarction.
This medication should not be given to patients with moderate to severe impaired kidney function, acute and unstable heart failure, patients scheduled for tests using radiopaque agents, and women who are pregnant or nursing.
During treatment, irregular meals, intense exercise, or interactions with other medications may increase the risk of hypoglycemia or lactic acidosis, so caution is required.
Periodic monitoring of kidney function, blood tests, and vitamin B12 levels should be conducted during the course of treatment, and alcohol consumption should be avoided.
Before and after surgery, this medication may need to be discontinued for a certain period, and if severe joint pain, skin rash, or blisters appear, you should notify your doctor immediately and seek medical attention.
Lastly, this medication can induce hypoglycemia, so when taken with insulin or sulfonylureas, hypoglycemic symptoms should be carefully monitored.
Side effects
Anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory infection
headache
nausea
Show 16 moreCollapse
vomiting
abdominal pain
nasopharyngitis
constipation
severe and disabling arthralgia
blistering similar to pemphigus
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
rhabdomyolysis
rash
urticaria
cutaneous vasculitis
Not everyone experiences these, and they can vary from person to person.
Storage
Store this medication in a tightly sealed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius. This will help preserve the effectiveness of the medication for a longer period.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.